Skip to main content
Premium Trial:

Request an Annual Quote

Biocartis Nabs CE Mark for Lung Cancer Test

NEW YORK – Belgian diagnostic firm Biocartis announced on Monday that its Idylla GeneFusion Panel for lung cancer has received CE-IVD marking. 

The test simultaneously detects ALK, ROS1, RET, and MET exon 14 skipping, actionable targets relevant in non-small cell lung cancer, in three hours. The automated panel is designed for use in clinical labs and can be used to guide therapy choices, the company said in a statement. 

The test also requires a limited amount of sample, "thereby saving valuable tissue specimens," the firm said. 

In 2020, Biocartis received a €1.2 million ($1.3 million) grant from Belgium's Agency for Innovation and Entrepreneurship to develop the test, and it launched the panel as a research-use-only assay in 2021. 

"Turnaround time and time to treatment remains an important barrier to molecular testing," Biocartis CEO Herman Verrelst said in a statement. "It has been demonstrated that 10 percent to 20 percent of advanced lung cancer patients do not receive the appropriate targeted therapy because biomarker results are not provided in a timely fashion." With the new Biocartis panel, "laboratories will have a rapid, actionable, and in-house solution at their disposal which can be seamlessly integrated into virtually any laboratory workflow." 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.